Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome.
CONCLUSIONS: Letrozole appears to improve live birth and pregnancy rates in subfertile women with anovulatory polycystic ovary syndrome, compared to clomiphene citrate. There is high-quality evidence that OHSS rates are similar with letrozole or clomiphene citrate. There is high-quality evidence of no difference in miscarriage rates or multiple pregnancy rates. There is low-quality evidence of no difference in live birth and pregnancy rates between letrozole and laparoscopic ovarian drilling, although there were few relevant studies. For the 2018 update, we added good-quality trials, upgrading the quality of the evidence.
PMID: 29797697 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Franik S, Eltrop SM, Kremer JA, Kiesel L, Farquhar C Tags: Cochrane Database Syst Rev Source Type: research
More News: Arimidex | Clinical Trials | Clomid | Databases & Libraries | General Medicine | Hormones | International Medicine & Public Health | Laparoscopy | Miscarriage | OBGYN | Ovaries | Polycystic Ovary Syndrome | Pregnancy | Reproduction Medicine | Study | WHO | Women